Clinical Trial Update: Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection [Phase 3]

View source ↗

Summary

The document provides an update on the efficacy and safety of Peginterferon Alfacon-2 in a Phase 3 study for chronic hepatitis B, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Peginterferon Alfacon-2 (Peginterferon alfacon-2)

Snippet

Sponsor: Beijing Kawin Technology Share-Holding Co., Ltd. | Conditions: Chronic Hepatitis B Virus Infection | Phase 3 | Status: COMPLETED